- Home
- PHAT vs STOK Comparison
PHAT vs STOK Comparison
Compare PHAT & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- STOK
- Stock Information
- Founded
- PHAT 2018
- STOK 2014
- Country
- PHAT United States
- STOK United States
- Employees
- PHAT N/A
- STOK N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- PHAT Health Care
- STOK Health Care
- Exchange
- PHAT Nasdaq
- STOK Nasdaq
- Market Cap
- PHAT 465.0M
- STOK 556.7M
- IPO Year
- PHAT 2019
- STOK 2019
- Fundamental
- Price
- PHAT $5.67
- STOK $8.33
- Analyst Decision
- PHAT Strong Buy
- STOK Strong Buy
- Analyst Count
- PHAT 4
- STOK 8
- Target Price
- PHAT $23.00
- STOK $23.83
- AVG Volume (30 Days)
- PHAT 1.0M
- STOK 830.1K
- Earning Date
- PHAT 03-06-2025
- STOK 03-24-2025
- Dividend Yield
- PHAT N/A
- STOK N/A
- EPS Growth
- PHAT N/A
- STOK N/A
- EPS
- PHAT N/A
- STOK N/A
- Revenue
- PHAT $26,270,000.00
- STOK $16,742,999.00
- Revenue This Year
- PHAT $7,453.23
- STOK $105.42
- Revenue Next Year
- PHAT $226.38
- STOK $15.13
- P/E Ratio
- PHAT N/A
- STOK N/A
- Revenue Growth
- PHAT N/A
- STOK 81.08
- 52 Week Low
- PHAT $5.21
- STOK $5.28
- 52 Week High
- PHAT $19.71
- STOK $17.58
- Technical
- Relative Strength Index (RSI)
- PHAT 39.59
- STOK 32.00
- Support Level
- PHAT $5.50
- STOK $9.76
- Resistance Level
- PHAT $6.21
- STOK $11.11
- Average True Range (ATR)
- PHAT 0.40
- STOK 0.88
- MACD
- PHAT 0.07
- STOK -0.30
- Stochastic Oscillator
- PHAT 38.69
- STOK 2.31
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is engaged in addressing the underlying causes of severe diseases by upregulating protein expression with RNA-based medicines. Using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, it is developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its first compound, STK-001, is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company primarily operates in the U.S.